We turn science
into medicine.

Angiolutions is the first company

to develop a device for small

abdominal aortic aneurysm therapy.


The human cardiovascular system is permanently generating mechanical forces enabling its physiological hemodynamic function. Therefore, our heart and all blood vessels are continuously exposed to significant biomechanical stress.

Adverse biomechanical forces significantly influence onset and progression of many cardiovascular diseases.

At Angiolutions, we understand that sufficient biomechanical organ protection is key to the prevention and treatment of numerous cardiovascular diseases. Following this philosophy, we combine latest medical, biophysical, and molecular research with state-of-the art engineering to create novel mechano-protective devices and realize truly innovative treatment strategies for millions of cardiovascular patients in need.


Angiolutions develops the world‘s first device to prevent small abdominal aortic aneurysm (AAA) progression and thereby revolutionizes the way AAA are treated today.

AAAs are focal dilations of the abdominal aorta that may grow and eventually rupture fatally. That’s why AAAs sometimes are called ticking time bombs.

While patients with large AAAs may receive prosthetic treatments to reduce the risk of imminent rupture, there presently is no therapy available for patients with small AAAs to prevent the life-threatening disease progression at a still relatively harmless stage.

Based on latest research findings, Angiolutions is pioneering the development of a first-of-its-kind minimally invasive device to prevent small AAAs progression, stop the ticking time bomb, and bring back peace of mind to thousands of patients.

About us

Angiolutions’ leadership team: Co-founders and Co-CEOs Dr. Uwe Raaz & Dr. Isabel N. Schellinger and Chief Business Officer Marius Rummel. Together, they lead a diverse, interdisciplinary team that is complemented by a board of industry veterans, top clinicians and leading researchers.


Forbes - 30 under 30

TMC X Companies


Winner MedTech Bootcamp

MIT Technology Review

Stay in touch

receive update emails a few times a year


Please leave your message here